U.S. Consumer Finance Stock News

Carvana just gave investors a sentiment whiplash. The stock closed at US$66.32 before the earnings release and then fell about 7% to US$61.44, even as the company reported record quarterly revenue of US$7.376b and a trailing net profit margin of 6.3%. The market is cooling on the story at the very moment the financials show the used car retailer solidly in the black. The real fault line is valuation. Carvana trades on a P/E of 28.2x against a peer group closer to 20x, while the share price...

Moelis stock jumped about 4.8% to US$68.35 into the close, which indicates that investors liked what they saw. The real story is not a one day pop. It is that Moelis just reported record Q2 2026 revenue of about US$409 million with an adjusted pretax margin near 18.6% in a fee based advisory business where margins drive sentiment. The move in the share price aligns closely with that margin story. The compensation ratio stepped down to roughly 65.8%, which signals to the market that Moelis is...

Old Dominion Freight Line stock gave up 4.6% today, even though the latest quarter delivered exactly what long term holders usually want from a less than truckload carrier. Revenue reached US$1.55b while basic earnings per share came in at US$1.69, matching the company’s record. The real story sat in profitability, with management reporting an operating ratio of 70.1%, which is very lean for this industry. Short term traders focused on the price drop. Long term investors are more likely to...

Vertiv Holdings came into this print looking tired, with the stock down over 30% in the last three months, yet the market snapped back on the release, pushing the shares up about 2% on the day. The move reflects how hard it is to square a weak recent chart with the strength of the latest earnings story. Vertiv just posted around US$3.27b of Q2 revenue and roughly US$1.29 of basic earnings per share, while trailing P/E sits near 50.5x. For a premium priced data center infrastructure stock,...

Teladoc Health just gave shareholders a brutal reminder that cheap can always get cheaper. The stock closed at US$9.18 before the report and is now marked around US$6.58, a slide of more than 28% that wipes out the recent 7 day and 30 day bounce attempts. Yet the headline from the quarter is not a collapse in the core virtual care engine. The story is a pressure point in BetterHelp, where falling cash pay revenue and a thin margin are colliding with a long term bet on insurance based...

The market barely flinched on ArcBest’s Q2 release. The stock inched up about 0.4% despite a headline that, on paper, looks far more dramatic than that move suggests. ArcBest posted a Q2 net loss and negative basic earnings per share while still delivering higher revenue and stronger non GAAP operating income. This is a margin story more than a growth story. Freight investors are weighing a reported loss that reflects heavy restructuring and impairment charges against an improving operating...

The market barely flinched on Humana’s earnings, with the stock up just 0.3% around US$366. That muted move sits against a report defined by margin repair rather than headline growth. Quarterly basic earnings per share of US$5.78 and net income of US$694m came alongside a clear message. Management is leaning hard into restoring Medicare Advantage profitability after a year of thinner margins and a large one off loss in the trailing period. For investors, the real story is whether this slow...

United Natural Foods recently reported that its natural product sales grew more than 4% in fiscal 2026, while it rolled out new digital tools, refreshed private-label offerings, and continued heavy investment in modernizing its supply-chain operations. This combination of category growth and technology-driven efficiency initiatives underscores how UNFI is trying to reinforce its role as a key distributor for health-focused retailers and brands. Next, we’ll examine how UNFI’s renewed push...

In the past quarter, Lincoln Electric Holdings, Inc. reported second-quarter 2026 sales of US$1,219.66 million and net income of US$158.52 million, with diluted earnings per share from continuing operations of US$2.88, and affirmed a quarterly dividend of US$0.79 per share payable on October 15, 2026. Beyond the headline growth, Lincoln Electric’s ability to expand earnings while keeping operating margins stable suggests cost discipline is supporting its higher revenue base. We’ll now...

Watsco came into this earnings print with the stock drifting lower for months and another 2.9% slide today, despite posting one of its seasonally strongest quarters. The market is leaning away from the long term HVAC distribution story just as the company reported US$2.1b in Q2 revenue and US$4.28 in basic earnings per share. The headline is not growth at any cost. Investors are focusing on margins. Gross margin landed at 27.5% and trailing net margin sits at 6.1%, both a step down from a...

New Oriental Education & Technology Group saw its stock slip 3.4% to US$56.58, even though the headline number pointed in the opposite emotional direction for many investors. Revenue in the latest quarter reached US$1,529.5m and non GAAP operating income came in at US$110m, which management framed as part of a broader profitability push. The tension today sits squarely between a premium P/E of 18.9x and a business still delivering earnings growth and higher net profit margins. The price fall...

Eastman Chemical Company has reported its second-quarter 2026 results, with sales of US$2,513 million and net income of US$183 million, both higher than the same period a year earlier. While quarterly earnings per share increased year over year, the six-month figures show lower net income and EPS compared with the prior-year period, highlighting a mixed profitability trend beneath the headline growth. We’ll now examine how this mix of higher quarterly sales and income but softer year-to-date...

In recent weeks, Cynosure Partners and Hamilton Lane closed a single-asset continuation vehicle in which Hamilton Lane committed a US$270 million minority stake to Savant Wealth Management, providing liquidity to early Savant partners while keeping existing minority holders, including Kelso & Company and Savant employees, in place. The deal underlines Hamilton Lane’s push deeper into the wealth management ecosystem, highlighting its appetite for complex continuation structures at the same...

Lincoln Financial Group (NYSE:LNC) has entered a reinsurance agreement with Talcott Financial Group covering a large portion of its guaranteed universal life portfolio. The deal transfers US$5.8b of in force guaranteed universal life reserves, which represents about 37% of Lincoln Financial's remaining GUL block. The transaction is intended to reduce exposure to capital intensive legacy policies and adjust future subsidiary cash remittances. For investors following Lincoln Financial, this...

Enterprise Products Partners has delivered a 146.4% total return over the past five years, yet the latest valuation checks send a more measured signal about how much upside might still be left in the current price of US$38.12. A 146.4% return over five years points to a stock that has already rewarded patient holders, which raises the bar for any new valuation upside. Future cash flow resilience from its midstream infrastructure can support current pricing, while any sustained pressure on...

In July 2026, Celcuity announced that its drug REVTORPYK (gedatolisib) received FDA approval and NCCN Category 1 preferred guideline status for use with fulvestrant, with or without palbociclib, in adults with HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation after progression on endocrine therapy. A key differentiator is that REVTORPYK is the only FDA-approved therapy targeting all class I PI3K isoforms and both mTORC1 and mTORC2 complexes, supported by...

Range Resources Corporation recently reported its second-quarter 2026 results, with revenue of US$833.57 million and net income of US$195.32 million, alongside an update that it repurchased 2,000,000 shares for US$78.35 million, completing a total buyback of 35,915,000 shares under its 2019 authorization. While quarterly revenue and earnings were lower than a year earlier, the company’s stronger first-half results and completion of a multi-year buyback program highlight how capital returns...

In July 2026, AbCellera Biologics announced a collaboration with Vertex Pharmaceuticals to research, develop, manufacture, and commercialize multispecific T-cell engagers for autoimmune diseases and other conditions, with Vertex funding all R&D and retaining commercialization rights while AbCellera receives US$28 million upfront plus potential milestones and royalties. This alliance adds an immunology-focused antibody platform to Vertex’s existing genetic medicine strengths, potentially...

Solstice Advanced Materials stock has given investors a sharp correction in the past month, yet the current market-multiple view still leans on the expensive side and the broader valuation checks only offer a mixed verdict rather than a clear bargain. The share price is down 35.2% over the past month, which pressures confidence in how much investors are willing to pay for the stock right now. The planned acquisition of Element Solutions may support expectations for a larger advanced...

KBR (NYSE:KBR) has named its planned independent Mission Technology Solutions spin-off "Trinzic." The company also announced executive designations for Trinzic as part of the separation process. This move marks a further step toward formally separating the Mission Technology Solutions business from KBR. KBR operates across government services and technology-focused engineering, with Mission Technology Solutions playing a central role in its defense and intelligence-facing work. The formal...

SELLAS Life Sciences Group (SLS) is back in focus as investors watch for the final analysis of its Phase 3 REGAL trial in acute myeloid leukemia, with the pivotal readout reportedly close. See our latest analysis for SELLAS Life Sciences Group. At a share price of $10.29, SELLAS Life Sciences Group has seen a very large 1 year total shareholder return. The 90 day share price return of 108.72% contrasts with a 30 day share price decline of 30.28%, suggesting momentum has cooled as investors...

Rithm Capital (NYSE:RITM) is weighing a potential shift from its current real estate investment trust structure to a traditional C corporation, according to recent management commentary. The company is also working to expand its third party asset management platform and grow fee based revenue streams. Rithm Capital enters this decision point with shares recently trading around $9.87. The stock is up 9.9% over the past week and 5.1% over the past month, while returns year to date and over...

Hercules Capital stock is coming off a solid 5 year return, yet current checks suggest the market price may still sit below what its fundamentals imply. At the last close of US$15.94, both the intrinsic value estimate from the Excess Returns model and the earnings multiple view point to a market that may be underpricing the company. Hercules Capital has returned 60.3% over the past 5 years, which puts recent short term weakness into a longer term context of gains. Future lending growth and...

TeraWulf stock has delivered a very large 3 year gain, yet its current valuation checks do not flag it as a clear bargain. After a sharp run and recent pullback, investors are left weighing strong past returns against a weak overall value score. Over the past 3 years, TeraWulf has returned about 5.8x, which puts extra focus on whether today’s price still leaves much room for error. Recent attention around AI data center financing and sector deals may support growth expectations for TeraWulf,...